Acupuncture vs. Massage for Insomnia and Pain in Advanced Cancer: Exploratory RCT.

J Pain Symptom ManageJul 18, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Eunbin Kwag, Rose W Y Fok, Qing S Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial compared acupuncture and massage therapy for treating insomnia in 234 patients with advanced cancer and baseline insomnia. Both interventions significantly improved insomnia severity scores at week 10, with no significant difference between groups (ISI reduction of -3.86 for acupuncture vs -3.83 for massage, P = 0.91).

Key findings

  • Both acupuncture and massage improved insomnia severity scores at week 10 (ISI reduction of -3.86 and -3.83, respectively; both P < 0.0001).
  • Responder rates for insomnia were similar: 35.1% for acupuncture and 33.3% for massage.
  • Pain responder rates were higher for massage (62.9%) compared to acupuncture (48.0%).
  • Insomnia responders showed greater reductions in pain at weeks 10 and 26 (both P < 0.0001).

Why it matters

The findings highlight the effectiveness of both acupuncture and massage in managing insomnia among patients with advanced cancer, a population often facing multiple symptoms. Understanding the interplay between sleep and pain can inform integrative treatment strategies.

Source

Published in J Pain Symptom Manage. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.